XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (35,898,234) $ (20,769,250)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 731,629 702,918
Change in fair value of earn-out milestone liability (5,396,000) (1,622,000)
Stock-based compensation 2,673,034 3,759,737
Change in deferred income tax asset 462,377
Impairment of goodwill and in-process research and development 13,366,234 1,976,101
Amortization of deferred finance charges and debt discount associated with note payable 181,259 237,258
Net changes in:    
Accrued interest receivable on investment securities (20,088) (108,844)
Advances and deposits on clinical programs and other current assets (514,600) (786,718)
Other assets 133,489 (124,728)
Accounts payable – trade 1,039,372 302,404
Other accrued liabilities 1,072,529 247,142
Deferred revenue (500,000) (500,000)
Net cash used in operating activities (23,131,376) (16,223,603)
Cash flows from investing activities:    
Purchases of investment in debt securities (48,191,922) (53,811,069)
Proceeds from sale and maturity of investment in debt securities 56,775,000 24,000,000
Purchases of property and equipment (267,800) (311,613)
Net cash used in investing activities 8,315,278 (30,122,682)
Cash flows from financing activities:    
Proceeds from redeemable convertible preferred stock offering 28,500,000
Payment upon redemption of redeemable convertible preferred stock (28,500,000)
Proceeds from issuance of common stock equity, net of issuance costs 6,722,667 52,688,946
Proceeds from issuance of common stock upon exercise of warrants 1,508,666
Proceeds from issuance of common stock upon exercise of stock options 4,725
Proceeds from notes payable 5,756,630
Payments on notes payable including end-of-term fees (5,190,587)
Net cash provided by financing activities 6,722,667 54,768,380
Change in cash, cash equivalents and restricted cash (8,093,431) 8,422,095
Cash, cash equivalents and restricted cash at beginning of year 25,586,272 17,164,177
Cash, cash equivalents and restricted cash at end of year 17,492,841 25,586,272
Supplemental disclosure of cash flow information:    
Interest (4,847,359) (357,277)
Cash paid for amounts included in measurement of lease liabilities:    
Operating cash flows from lease payments 601,495 568,269
Realized and unrealized gains, net, on investment in debt securities $ 26,494 $ 7,974